The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.
This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.
Key Practical Learning Points of the Summit:
- Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
- Ensure product and process robustness
- Make more evidence-based decisions
- Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
- Learn about advances in Protein Modeling and Engineering Breakthroughs
- How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
- Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
- Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
- Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity
Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:
- Toxicology
- Biologics
- Molecular Biology
- Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
- Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
- Oncology Drug Development; Oncology Molecules
- Medical information
- Bioanalytical
- Discovery Chemistry; Research & Development; Antibody Discovery
- Protein Engineering; Process Sciences
- Biopharmaceutical Development; Development Analytics and New Technologies:
- Clinical Assay; Biologics Discovery and Design
It is also designed for professionals who work for the Industry of:
- Pharmaceuticals,
- Biologics,
- Medicine;
- Clinical Research Organizations;
- Academic Research Centers;
- Regulatory Agencies